In a new JAMA Oncology study, Biagio Ricciuti, MD, PhD Dana-Farber found chemoimmunotherapy before surgery may offer a path forward for patients with advanced stage III non-small cell lung cancer. Read more: bit.ly/445t1li

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer buff.ly/WnSosZu This multicenter cohort study evaluated the efficacy of neoadjuvant PD-1/PD-L1 blockade combined with platinum-based

Listen to this week's episode of the VJOncology Podcasts featuring João Alessi, MD and Alessandro Di Federico who discussed #LungCancer updates from #ASCO25 🎧Listen here tinyurl.com/yf7f3az7 They explore the potential of new agents like tarlatamab, and dive into pivotal trials in

Pleased to discuss some of the ASCO 2025 lung cancer highlights with my dear friend and colleague João Alessi, MD in this VJ Oncology podcast 👇

Our VJ Oncology discussion on lung cancer highlights from #ASCO25 with João Alessi, MD is also available on YouTube 👇 IASLC ASCO OncoAlert EGFR Resisters OncoDaily youtube.com/watch?v=MPmobo…

Pulmonary sarcomatoid carcinoma is a rare NSCLC histology that every thoracic oncologist has or will face in their practice. In this study led by Dr. Lingzhi Hong & Natalie Vokes MD Anderson Cancer Center, we characterized features & outcomes of patients w/ these tumors jto.org/article/S1556-…

New in JTO & JTO CRR - reinforces findings from this recent paper on pulmonary sarcomatoid carcinomas [👉🏽 sciencedirect.com/science/articl… ] with some interesting nuances ➡️ Chemo doesn’t add to benefit of ICI, esp for pleomorphic subtype. ➡️ Small numbers, but no difference between taxol

Emre Yekedüz Yüksel Ürün Bonum CE Enrique Grande Shilpa Gupta Matt Galsky Andrea Apolo, M.D. Petros Grivas joaquim bellmunt Andrea Necchi Xinan Sheng Tom Powles Oncology Brothers Dr Joseph McCollom DO Dra. María Natalia Gandur Quiroga Bárbara Melão, MD, PhD Neeraj Agarwal, MD, FASCO Pedro C Barata, MD MSc FACP Dr. Bishoy M. Faltas #TumorBoardTuesday And stay tuned #TumorBoardTuesday as next week Biagio Ricciuti, MD PhD & Alessandro Di Federico 🗣️Frontline IO Strategies for STK11/KEAP1-Mutant mNSCLC

An important question in #BRAF+ #NSCLC — targeted therapy or #ICI first? Factors like PD-L1, smoking history, and CNS involvement may guide us. More to come from our global effort led by Alessandro Di Federico. OncoAlert Dana-Farber Fawzi Abu Rous, MD Marcelo Negrao Marina Garassino IASLC

On Tuesday, August 5, from 8 to 9 PM ET, Biagio Ricciuti, MD, PhD and I will be discussing what we currently know about the treatment of patients with advanced NSCLC harboring mutations in STK11 and/or KEAP1 #TumorBoardTuesday

#TumorBoardTuesday 🫁Move back to Lung Cancer #NSCLC 📢Join us Tuesday, 08-05-25 at 8PM ET as @biagioricciutMD & Alessandro Di Federico 🗣️Frontline IO Strategies for STK11/KEAP1-Mutant metastatic #NSCLC RT and bring others into the discussion‼️

Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO 3/20 | #TumorBoardTuesday All 3 approaches are valid in PD-L1 ≥1% NSCLC. E.g., at 5 years: ✅ Pembrolizumab mono (KN042): OS 16.4 mo | HR 0.79 ✅ Pembrolizumab + chemo (KN189): OS 24.7 mo | HR 0.66 ✅ Nivo + Ipi + chemo (CM9LA): OS 15.8 mo | HR 0.73 But context matters...

Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO 4/20 | #TumorBoardTuesday While KEYNOTE-042 showed OS benefit for pembro monotherapy in PD-L1 ≥1%, this was driven by the ≥50% subgroup. In patients with PD-L1 1–49%, there was no OS advantage over chemo—underscoring the limited efficacy of pembro monotherapy in this group

Biagio Ricciuti, MD, PhD #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO 7/20 | #TumorBoardTuesday These mutations confer poor prognosis even among cases with PD-L1 ≥50% treated with PD-(L)1 inhibitor monotherapy.

Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO 8/20 | #TumorBoardTuesday Importantly, this negative impact also extends to chemo-immunotherapy and #KRAS inhibitors, (especially KEAP1) 👉 reinforcing a prognostic (not purely predictive) role for STK11/KEAP1 alterations. João Alessi, MD

Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO 9/20 | #TumorBoardTuesday So—how do we treat STK11/KEAP1-mutant cases? 👉 Evidence suggests intensified approaches, such as chemo + PD-(L)1 ± CTLA-4 blockade, might be beneficial in certain circumstances (e.g., PD-L1<1%; STK11 & KEAP1 co-mutations or w/ KRAS. Marina Garassino

Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO Marina Garassino 19/20 | #TumorBoardTuesday 🔑 Takeaways (2/2): Genomic profiling is critical beyond just targeted therapy 🧬 NGS informs immunotherapy strategies too! ➡️ STK11, KEAP1, (among others!)., can guide immunotherapy-based intensification approaches

Biagio Ricciuti, MD, PhD Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO Marina Garassino Glad i was able to STK it out to the end- great #TumorBoardTuesday !

Biagio Ricciuti, MD, PhD Alessandro Di Federico #TumorBoardTuesday Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO Marina Garassino Less chemo and dual ICI..#tumorboardtues

Alessandro Di Federico Biagio Ricciuti, MD, PhD Biagio Ricciuti, MD PhD Integrity CE, LLC João Alessi, MD Federica Pecci Roberto Ferrara Narjust Florez, MD, FASCO Marcelo Corassa, MD. Mark Awad Stephen V Liu, MD Balazs Halmos Paolo Tarantino Edoardo Garbo Ferdinandos Skoulidis Fawzi Abu Rous, MD Aakash Desai, MD, MPH, FASCO Rafeh Naqash, MD Alessio Cortellini Christian Rolfo Adam Barsouk MD Alfredo Addeo MD Eric K. Singhi, MD H. Jack West, MD, FASCO Marina Garassino #TumorBoardTuesday Thank you so much Biagio Ricciuti, MD, PhD & Alessandro Di Federico for such an insightful discussion‼️ That was the epitome of a tag-teaming dual effort🤣